1665 related articles for article (PubMed ID: 18166815)
1. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
[TBL] [Abstract][Full Text] [Related]
2. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.
Lund SS; Tarnow L; Stehouwer CD; Schalkwijk CG; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag A
Diabetes Obes Metab; 2007 May; 9(3):394-407. PubMed ID: 17391168
[TBL] [Abstract][Full Text] [Related]
3. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes.
Lund SS; Tarnow L; Stehouwer CD; Schalkwijk CG; Teerlink T; Gram J; Winther K; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
Eur J Endocrinol; 2008 May; 158(5):631-41. PubMed ID: 18426821
[TBL] [Abstract][Full Text] [Related]
4. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control.
Chisalita SI; Lindström T; Eson Jennersjö P; Paulsson JF; Westermark GT; Olsson AG; Arnqvist HJ
Acta Diabetol; 2009 Mar; 46(1):35-42. PubMed ID: 18777156
[TBL] [Abstract][Full Text] [Related]
5. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes.
Moses R; Slobodniuk R; Boyages S; Colagiuri S; Kidson W; Carter J; Donnelly T; Moffitt P; Hopkins H
Diabetes Care; 1999 Jan; 22(1):119-24. PubMed ID: 10333912
[TBL] [Abstract][Full Text] [Related]
6. Repaglinide has more beneficial effect on cardiovascular risk factors than glimepiride: data from meal-test study.
Rizzo MR; Barbieri M; Grella R; Passariello N; Paolisso G
Diabetes Metab; 2005 Jun; 31(3 Pt 1):255-60. PubMed ID: 16142016
[TBL] [Abstract][Full Text] [Related]
7. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
[TBL] [Abstract][Full Text] [Related]
8. Repaglinide--prandial glucose regulator: a new class of oral antidiabetic drugs.
Owens DR
Diabet Med; 1998; 15 Suppl 4():S28-36. PubMed ID: 9868989
[TBL] [Abstract][Full Text] [Related]
9. [The effect of metformin on fasting and postprandial insulin secretion in obese patients with diabetes mellitus type 2].
Vuković M; Lapcević M; Kalezić N; Gvozdenović BS
Srp Arh Celok Lek; 2007; 135(7-8):447-52. PubMed ID: 17929538
[TBL] [Abstract][Full Text] [Related]
10. Improved glycemic control induced by both metformin and repaglinide is associated with a reduction in blood levels of 3-deoxyglucosone in nonobese patients with type 2 diabetes.
Engelen L; Lund SS; Ferreira I; Tarnow L; Parving HH; Gram J; Winther K; Pedersen O; Teerlink T; Barto R; Stehouwer CD; Vaag AA; Schalkwijk CG
Eur J Endocrinol; 2011 Mar; 164(3):371-9. PubMed ID: 21205874
[TBL] [Abstract][Full Text] [Related]
11. Repaglinide improves blood glucose control in sulphonylurea-naive type 2 diabetes.
Van Gaal LF; Van Acker KL; De Leeuw IH
Diabetes Res Clin Pract; 2001 Sep; 53(3):141-8. PubMed ID: 11483229
[TBL] [Abstract][Full Text] [Related]
12. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review.
Johansen OE; Birkeland KI
Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471
[TBL] [Abstract][Full Text] [Related]
13. Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes.
Meneilly GS
Diabetes Technol Ther; 2011 Jan; 13(1):63-5. PubMed ID: 21175273
[TBL] [Abstract][Full Text] [Related]
14. Effect of repaglinide and gliclazide on glycaemic control, early-phase insulin secretion and lipid profiles in.
Zhang H; Bu P; Xie YH; Luo J; Lei MX; Mo ZH; Liao EY
Chin Med J (Engl); 2011 Jan; 124(2):172-6. PubMed ID: 21362360
[TBL] [Abstract][Full Text] [Related]
15. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
[TBL] [Abstract][Full Text] [Related]
16. Increased prandial insulin secretion after administration of a single preprandial oral dose of repaglinide in patients with type 2 diabetes.
Owens DR; Luzio SD; Ismail I; Bayer T
Diabetes Care; 2000 Apr; 23(4):518-23. PubMed ID: 10857945
[TBL] [Abstract][Full Text] [Related]
17. Comparison of glycaemic control and cardiovascular risk profile in patients with type 2 diabetes during treatment with either repaglinide or metformin.
Derosa G; Mugellini A; Ciccarelli L; Crescenzi G; Fogari R
Diabetes Res Clin Pract; 2003 Jun; 60(3):161-9. PubMed ID: 12757988
[TBL] [Abstract][Full Text] [Related]
18. Meal frequency; does it determine postprandial lipaemia?
Murphy MC; Chapman C; Lovegrove JA; Isherwood SG; Morgan LM; Wright JW; Williams CM
Eur J Clin Nutr; 1996 Aug; 50(8):491-7. PubMed ID: 8863008
[TBL] [Abstract][Full Text] [Related]
19. Modification of beta-cell response to different postprandial blood glucose concentrations by prandial repaglinide and combined acarbose/repaglinide application.
Rosak C; Hofmann U; Paulwitz O
Diabetes Nutr Metab; 2004 Jun; 17(3):137-42. PubMed ID: 15334790
[TBL] [Abstract][Full Text] [Related]
20. Repaglinide in combination therapy.
Moses R
Diabetes Nutr Metab; 2002 Dec; 15(6 Suppl):33-8. PubMed ID: 12702006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
